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 Teles and co-workers 1 (this issue) 
present experimental data addressing 
some of these issues. Rats with streptozo-
tocin-induced diabetes were treated with 
conventional (50  mg / kg / d) and extremely 
high (500  mg / kg / d) doses of the angi-
otensin receptor blocker (ARB) losartan. 
In contrast to most diabetic nephropathy 
studies, in which treatment is initiated 
around the time of onset of diabetes, the 
authors tested the e; ects of losartan in 
rats starting 10 months a1 er induction of 
diabetes, at a time when structural 
glomerular lesions were already present. 
Notably, this experimental design may 
more closely mimic the clinical situation, 
where nephroprotective treatment is not 
initiated until the patient exhibits incipi-
ent or overt nephropathy. 
 Treatment with losartan reduced pro-
teinuria to levels observed in control ani-
mals and led to regression of mesangial 
expansion to below pretreatment levels. In 
contrast, more advanced lesions (de3 ned 
by synechiae to Bowman ’ s space, capillary 
loop occlusion, more abundant deposition 
of periodic acid-Schiff (PAS)-positive 
material, and segmental hyalinization) 
were not a; ected. Representative phot-
omicrographs depicting these stages and 
the e; ects of RAS inhibition, from similar 
groups of rats studied in our laboratory, 
are shown in  Figure 1 (unpublished data). 
However, although treatment did not 
induce regression of these more advanced 
changes, it largely prevented the develop-
ment of new lesions. 2 us, the authors 
provide valuable information suggesting 
that dramatic reduction of proteinuria is 
associated with regression of mesangial 
expansion, without affecting more 
advanced glomerular lesions. 
 Teles  et al. 1 are to be commended for 
carefully di; erentiating between the vari-
ous morphologic parameters. Much of the 
existing literature regarding  ‘ regression ’ is 
far less precise. The term is often used 
clinically to refer to reduction in urinary 
albumin excretion rate, sometimes from 
microalbuminuria back down into the 
normal range. However, the vast majority 
of these studies do not include structural 
information, leaving open the important 
question of whether the reduction in 
urinary albumin excretion will have 
long-term significance with respect to 
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 Inhibitors of the renin – angiotensin – aldosterone system (RAS) exert 
beneficial effects in diabetic nephropathy, but the possibility of 
regression of existing renal lesions remains to be investigated. Teles  et al. 
tested the effects of the RAS inhibitor losartan in rats starting 10 months 
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present. They linked the reductions of proteinuria with regression of 
mesangial expansion. More advanced lesions were not affected. There 
were no dose – response renal effects of losartan. 
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 Inhibition of the renin – angiotensin –
 aldosterone system (RAS) plays a pivotal 
role in the prevention and treatment of 
diabetic nephropathy. A myriad of studies, 
including large multicenter randomized 
trials with patients at various stages of dia-
betic nephropathy, has well documented 
that treatment with RAS inhibitors can 
slow the progressive decrease in glomeru-
lar 3 ltration rate, reduce proteinuria and 
microalbuminuria, prevent transition 
from one stage of nephropathy to 
another, and reduce cardiovascular mor-
tality and morbidity. However, despite 
these documented beneficial effects 
of RAS inhibitors in diabetic patients 
with overt nephropathy, reversal of the 
progressive course of this disorder or at 
least long-term stabilization of renal 
function is diG  cult to achieve, and many 
patients still progress to end-stage renal 
disease. 
 Several reasons have been postulated 
for unsatisfactory therapeutic responses 
to RAS inhibition in some patients, 
including incomplete inhibition of the 
RAS, lack of effects on structural hall-
marks of diabetic nephropathy, and the 
question of reversibility of established 
renal lesions in these patients. 
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preservation of renal function and struc-
ture. Indeed, none of the available human 
biopsy studies has documented regression 
of structural lesions. 2 e investigators of 
the European Study for the Prevention of 
Renal Disease in Type 1 Diabetes 
(ESPRIT) 2 reported that in 15 normoten-
sive type 1 diabetic patients with an albu-
min excretion rate of 30 – 1500   g per 
minute, low-dose angiotensin-converting 
enzyme inhibitor (ACEI) treatment with 
enalapril (10  mg per day) for 3 years did 
not a; ect glomerular or interstitial struc-
tures. Indeed, there was no change in any 
structural parameter in the enalapril, 
nifedipine, or placebo group. Rudberg  et 
al. 3 compared renal structure before and 
a1 er 38 months of treatment with enal-
april or metoprolol in 13 type 1 diabetic 
patients with microalbuminuria, report-
ing no structural changes over time in 
either group. However, treatment with 
both antihypertensive drugs prevented the 
progression of lesions observed in the 
placebo-treated group. In addition, 
recently communicated results of the 
Renin – Angiotensin System Study 4 in nor-
moalbuminuric type 1 diabetic patients 
also indicate a lack of e; ect of ACEI on 
early structural glomerular markers of 
nephropathy. In 19 type 2 diabetic 
patients, treatment with the ACEI 
perindopril prevented the progression of 
interstitial 3 brosis in comparison with 
controls, without affecting glomerular 
structure. 5 2 us, RAS blockade, e; ective 
in slowing progression in type 1 diabetes, 6 
has not thus far been shown to have a 
favorable effect on renal structure in 
humans. 
 Several factors might explain these dis-
crepancies between the present experi-
mental study and corresponding clinical 
evidence. Sampling bias is likely. Whereas 
human biopsy studies allow investigation 
of just a few glomeruli in each patient, rat 
studies allow evaluation of whole kidney 
sections and tens to hundreds of glomeruli 
per animal. With respect to the consider-
ably lower number of glomeruli available 
for evaluation in human studies, it may be 
diG  cult to detect statistically signi3 cant 
changes induced by nephroprotective 
treatments in general. Secondly, diabetic 
nephropathy may simply be more RAS-
dependent in rats than in humans. 
 2 irdly, the available clinical studies 
with biopsy data may not have followed 
the patients for sufficient duration to 
detect structural changes. 2 us far, the 
only clinical evidence of regression of 
glomerular changes in humans was 
reported by Fioretto  et al. 7 in patients a1 er 
10 years of normoglycemia achieved by 
successful pancreas transplantation. Inter-
estingly, regression was not detected when 
the same patients were tested just 5 years 
a1 er transplantation. 8 It is therefore con-
ceivable that regression of lesions in 
response to RAS inhibition will require a 
substantially longer time in clinical stud-
ies. Indeed, available human biopsy studies 
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 Figure 1 |  Schematic presentation of findings by Teles  et al. 1 ( a ) When untreated, glomerular lesions in diabetic rats progress through the stage 
of mesangial expansion due to diffuse deposition of PAS-positive material to advanced lesions defined by synechiae to Bowman ’ s space, capillary 
loop occlusion, confluent deposition of PAS-positive material, and segmental hyalinization. ( b ) The antiproteinuric effect of losartan is associated 
with regression of mesangial expansion and diffuse glomerulosclerosis. In contrast, more advanced lesions are not affected. However, although the 
treatment did not induce regression of these more advanced changes, it largely prevented the development of new lesions. 
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evaluating the e; ects of RAS inhibitors 
have had follow-up of 3 – 5 years  – that is, 
insuG  cient duration even for expression 
of bene3 cial e; ects of normoglycemia. 
 In their previous work, Zatz and col-
leagues 9 have shown dose-dependent 
e; ects of losartan in 3 ve-sixths-nephrec-
tomized rats, a model of progressive 
nondiabetic glomerulosclerosis. In con-
trast, in the study by Teles  et al. , 1 even 
extremely high doses of losartan were not 
more e; ective in reducing proteinuria and 
mesangial expansion than the conven-
tional dose and did not affect more 
severely involved glomeruli. In clinical 
settings, the potential benefit of more 
complete inhibition of the RAS cascade is 
still debatable, in particular in the light of 
the most recently published results of 
multicenter trials. 
 For example, in contrast to the present 
experimental observations, Rossing 
 et al. 10 did provide evidence of a dose-
dependent e; ect of ARB therapy in dia-
betic nephropathy. Increasing the dose of 
irbesartan from 300 to 900  mg per day 
further reduced proteinuria in type 2 dia-
betic patients followed for 2 months. 
Similarly, addition of aliskiren, a renin 
inhibitor, to recommended doses of ACEIs 
or ARBs in type 2 diabetic patients with 
nephropathy resulted in a further decrease 
of proteinuria. 11 In contrast, results of the 
Irbesartan in the Management of Pro-
teinuric Patients at High Risk for Vascular 
Events (IMPROVE) study, 12 also con-
ducted predominantly in micro- and mac-
roalbuminuric patients with type 2 
diabetes, suggest no further benefit of 
strengthening the RAS inhibition by com-
bination of full doses of the ACEI ramipril 
and the ARB irbesartan, as compared with 
monotherapy with ramipril. However, a 
trend toward a stronger antiproteinuric 
e; ect of the combination was noted in 
patients with overt albuminuria     200   g 
per minute. In our opinion, the lack of a 
dose – response e; ect as observed by Teles 
 et al. 1 is not surprising. 2 e conventional 
dose of losartan was so e; ective in the 
treatment of proteinuria and structural 
alterations that little space was le1  for the 
higher dose to exert additional signi3 cant 
therapeutic e; ect. 2 e dose-dependent 
e; ect of ARBs in experimental diabetic 
nephropathy might be revealed when 
studied at lower dose ranges, or in a study 
in which the animals are followed for 
longer than the 2 months of therapy in the 
present study. More importantly, the avail-
able clinical studies of ultra-high-dose 
RAS inhibition are all short-term studies 
using only albuminuria as a marker of 
nephropathy. E; ects on structural lesions 
are unknown. 
 Reductions in proteinuria have been 
shown to be associated with better 
renal and cardiovascular long-term 
outcomes in patients with diabetic neph-
ropathy. 13 In this context, another impor-
tant question raised by the study of 
Teles  et al. 1 is whether reductions of 
proteinuria and regression in mesangial 
matrix expansion, but not more advanced 
lesions, would impact long-term preserva-
tion of glomerular 3 ltration rate. 2 is has 
become even more relevant in the light of 
recent analysis of renal outcomes in the 
large Ongoing Telmisartan Alone and in 
Combination with Ramipril Global 
Endpoint Trial (ONTARGET), 14 which 
included almost 7000 diabetic patients. 
In that study, RAS inhibition with a com-
bination of full doses of ACEI and ARB 
was more e; ective in reducing indices of 
urinary protein excretion than mono-
therapy with ramipril but failed to exert 
any bene3 cial e; ects on the primary com-
posite outcome (doubling of serum cre-
atinine, dialysis, and death). 2 is issue will 
be diG  cult to test in STZ-diabetic rats, 
which, unlike humans, do not develop 
progressive loss of glomerular 3 ltration 
rate. However, the authors might be 
encouraged by the present data to perform 
studies with longer follow-up a1 er initia-
tion of losartan treatment, or to select a 
more progressive model of diabetic kid-
ney disease. 
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